Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Public ClinicalTrials.gov record NCT01796470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Study identification
- NCT ID
- NCT01796470
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Interventions
- Entospletinib Drug
- Idelalisib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2013
- Primary completion
- Dec 31, 2014
- Completion
- Dec 21, 2016
- Last update posted
- Jun 1, 2020
2013 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Ventura County Hematology Oncology Specialists | Oxnard | California | 93030 | — |
| Cancer Center of Santa Barbara | Santa Barbara | California | 93105 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Collaborative Research Group LLC | Boynton Beach | Florida | 33435 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| University of Rochester, James P. Wilmot Cancer Center | Rochester | New York | 14642 | — |
| Signal Point Clinical Research Center, LLC | Middletown | Ohio | 45042 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Charleston Hematology Oncology | Charleston | South Carolina | 29414 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01796470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01796470 live on ClinicalTrials.gov.